Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Health Service Products (Provision and Disclosure of Information) Regulations 2018 on the costs of generic medicine or special medicinal product listed with a reimbursement price in the drug tariff.
The Government publishes an annual review on the Health Service Products (Provision and Disclosure of Information) Regulations 2018, which assesses the regulations against their objectives. The latest review can be found at the following link:
The collection of data under the regulations ensures reimbursement prices set using market data includes data from all suppliers and therefore the reimbursement price more fairly reflects the average market selling price. A number of factors effect both the selling and the reimbursement price.